The Transplant Company announced that it has submitted its comment letter in response to the draft Local Coverage Determination, LCD, related to molecular testing for solid organ transplant rejection.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- Hold Rating for CareDx Amid Revenue Uncertainties and Valuation Discount
- CareDx initiated with a Market Perform at William Blair
- Cathie Wood Buys $172M Worth of Bullish Stock (BLSH) on Blockbuster IPO Debut, Trims Stake in SHOP
- CareDx price target lowered to $22 from $26 at BTIG
- CareDx Inc. Reports Strong Growth Amid Challenges